TY - JOUR
T1 - Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment
AU - Ashraf, Shazia
AU - Kudo, Hiroki
AU - Rao, Jia
AU - Kikuchi, Atsuo
AU - Widmeier, Eugen
AU - Lawson, Jennifer A.
AU - Tan, Weizhen
AU - Hermle, Tobias
AU - Warejko, Jillian K.
AU - Shril, Shirlee
AU - Airik, Merlin
AU - Jobst-Schwan, Tilman
AU - Lovric, Svjetlana
AU - Braun, Daniela A.
AU - Gee, Heon Yung
AU - Schapiro, David
AU - Majmundar, Amar J.
AU - Sadowski, Carolin E.
AU - Pabst, Werner L.
AU - Daga, Ankana
AU - Van Der Ven, Amelie T.
AU - Schmidt, Johanna M.
AU - Low, Boon Chuan
AU - Gupta, Anjali Bansal
AU - Tripathi, Brajendra K.
AU - Wong, Jenny
AU - Campbell, Kirk
AU - Metcalfe, Kay
AU - Schanze, Denny
AU - Niihori, Tetsuya
AU - Kaito, Hiroshi
AU - Nozu, Kandai
AU - Tsukaguchi, Hiroyasu
AU - Tanaka, Ryojiro
AU - Hamahira, Kiyoshi
AU - Kobayashi, Yasuko
AU - Takizawa, Takumi
AU - Funayama, Ryo
AU - Nakayama, Keiko
AU - Aoki, Yoko
AU - Kumagai, Naonori
AU - Iijima, Kazumoto
AU - Fehrenbach, Henry
AU - Kari, Jameela A.
AU - El Desoky, Sherif
AU - Jalalah, Sawsan
AU - Bogdanovic, Radovan
AU - Stajić, Nataša
AU - Zappel, Hildegard
AU - Rakhmetova, Assel
AU - Wassmer, Sharon Rose
AU - Jungraithmayr, Therese
AU - Strehlau, Juergen
AU - Kumar, Aravind Selvin
AU - Bagga, Arvind
AU - Soliman, Neveen A.
AU - Mane, Shrikant M.
AU - Kaufman, Lewis
AU - Lowy, Douglas R.
AU - Jairajpuri, Mohamad A.
AU - Lifton, Richard P.
AU - Pei, York
AU - Zenker, Martin
AU - Kure, Shigeo
AU - Hildebrandt, Friedhelm
N1 - Funding Information:
We are grateful to study individuals for their contribution. We acknowledge the Yale Center for Mendelian Genomics for whole exome sequencing. This research was supported by grants from the National Institutes of Health to F.H. (DK076683) and by the Howard Hughes Medical Institute to F.H. F.H. is the William E. Harmon Professor of Pediatrics. E.W. is supported by the German National Academy of Sciences Leopoldina (LPDS-2015-07). W.T. is supported by the ASN Foundation for Kidney Research. T.H. is supported by the DFG-fellowship (HE 7456/1-1). T.J.S. is supported by the Deutsche Forschungsgemeinschaft (Jo 1324/1-1). H.Y.G. is supported by the National Research Foundation of Korea, Ministry of Science, ICT, and Future planning (2015R1D1A1A01056685) and faculty seed money from the Yonsei University College of Medicine (2015-32-0047). A.T.v.d.V. is supported by the DFG-fellowship (VE 196/1-1). We thank Yoko Chiba, Kumi Ito, Miyuki Tsuda, Mami Kikuchi, Makiko Nakagawa, Yoko Tateda and Kiyotaka Kuroda for their technical assistance. This work was supported by grants (17ek0109151h0003 and 17ek0109278h0001) from Japan Agency for Medical Research and Development (AMED) to S.K. We acknowledge the support of the Biomedical Research Unit of Tohoku University Hospital and the Biomedical Research Core and the Institute for Animal Experimentation of Tohoku University Graduate School of Medicine. N.A.S is supported by the Egyptian Group for Orphan Renal Diseases (EGORD). M.A.J. is supported by Department of Science and Technology, Govt. of India (DST-SERB). M.Z. was supported by the Deutsche Forschungsgemeinschaft (SFB423).
Funding Information:
This research was supported by grants from the National Institutes of Health to F.H. (DK076683) and by the Howard Hughes Medical Institute to F.H. F.H. is the William E. Harmon Professor of Pediatrics. E.W. is supported by the German National Academy of Sciences Leopoldina (LPDS-2015-07). W.T. is supported by the ASN Foundation for Kidney Research. T.H. is supported by the DFG-fellowship (HE 7456/1-1). T.J.S. is supported by the Deutsche Forschungsgemeinschaft (Jo 1324/1-1). H.Y.G. is supported by the National Research Foundation of Korea, Ministry of Science, ICT, and Future planning (2015R1D1A1A01056685) and faculty seed money from the Yonsei University College of Medicine (2015-32-0047). A.T.v.d.V. is supported by the DFG-fellowship (VE 196/1-1). We thank Yoko Chiba, Kumi Ito, Miyuki Tsuda, Mami Kikuchi, Makiko Nakagawa, Yoko Tateda and Kiyotaka Kuroda for their technical assistance. This work was supported by grants (17ek0109151h0003 and 17ek0109278h0001) from Japan Agency for Medical Research and Development (AMED) to S.K. We acknowledge the support of the Biomedical Research Unit of Tohoku University Hospital and the Biomedical Research Core and the Institute for Animal Experimentation of Tohoku University Graduate School of Medicine. N.A.S is supported by the Egyptian Group for Orphan Renal Diseases (EGORD). M.A.J. is supported by Department of Science and Technology, Govt. of India (DST-SERB). M.Z. was supported by the Deutsche Forschungsgemeinschaft (SFB423)
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - No efficient treatment exists for nephrotic syndrome (NS), a frequent cause of chronic kidney disease. Here we show mutations in six different genes (MAGI2, TNS2, DLC1, CDK20, ITSN1, ITSN2) as causing NS in 17 families with partially treatment-sensitive NS (pTSNS). These proteins interact and we delineate their roles in Rho-like small GTPase (RLSG) activity, and demonstrate deficiency for mutants of pTSNS patients. We find that CDK20 regulates DLC1. Knockdown of MAGI2, DLC1, or CDK20 in cultured podocytes reduces migration rate. Treatment with dexamethasone abolishes RhoA activation by knockdown of DLC1 or CDK20 indicating that steroid treatment in patients with pTSNS and mutations in these genes is mediated by this RLSG module. Furthermore, we discover ITSN1 and ITSN2 as podocytic guanine nucleotide exchange factors for Cdc42. We generate Itsn2-L knockout mice that recapitulate the mild NS phenotype. We, thus, define a functional network of RhoA regulation, thereby revealing potential therapeutic targets.
AB - No efficient treatment exists for nephrotic syndrome (NS), a frequent cause of chronic kidney disease. Here we show mutations in six different genes (MAGI2, TNS2, DLC1, CDK20, ITSN1, ITSN2) as causing NS in 17 families with partially treatment-sensitive NS (pTSNS). These proteins interact and we delineate their roles in Rho-like small GTPase (RLSG) activity, and demonstrate deficiency for mutants of pTSNS patients. We find that CDK20 regulates DLC1. Knockdown of MAGI2, DLC1, or CDK20 in cultured podocytes reduces migration rate. Treatment with dexamethasone abolishes RhoA activation by knockdown of DLC1 or CDK20 indicating that steroid treatment in patients with pTSNS and mutations in these genes is mediated by this RLSG module. Furthermore, we discover ITSN1 and ITSN2 as podocytic guanine nucleotide exchange factors for Cdc42. We generate Itsn2-L knockout mice that recapitulate the mild NS phenotype. We, thus, define a functional network of RhoA regulation, thereby revealing potential therapeutic targets.
UR - http://www.scopus.com/inward/record.url?scp=85047275091&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047275091&partnerID=8YFLogxK
U2 - 10.1038/s41467-018-04193-w
DO - 10.1038/s41467-018-04193-w
M3 - Article
C2 - 29773874
AN - SCOPUS:85047275091
SN - 2041-1723
VL - 9
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1960
ER -